Chemomab Therapeutics Ltd.
Every calculator, already run for CMMB
Open the full toolkit →You have the numbers on CMMB. Get the argument.
A written report on which of these readings actually decide the outcome for Chemomab Therapeutics Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering CMMBOwnership & short interest
Insider Trading Activity for CMMB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
CMMB — frequently asked
Is CMMB a buy right now?
Wall Street's consensus rating on Chemomab Therapeutics Ltd. is none across 1 analysts, with a mean price target of $5.00 (+98% vs. the current $2.52). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Chemomab Therapeutics Ltd. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Chemomab Therapeutics Ltd.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CMMB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Chemomab Therapeutics Ltd., in minutes. 3 free reports included with every account — no credit card required.